Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark E Cooper

Showing results (81-90 of 399) with videos related to

Pageof 40
Sort By:
Lancet (London, England)|December 10, 2013
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and futureSteven E Kahn, Mark E Cooper, Stefano Del Prato
Current Atherosclerosis Reports|April 8, 2004
Use of genetic mouse models in the study of diabetic nephropathyTerri J Allen, Mark E Cooper, Hui Y Lan
Annals of the New York Academy of Sciences|May 2, 2008
Therapeutic interruption of advanced glycation in diabetic nephropathy: do all roads lead to Rome?Karly C Sourris, Josephine M Forbes, Mark E Cooper
Kidney International|September 17, 2005
Targets to retard the progression of diabetic nephropathyMark E Cooper, Karin Jandeleit-Dahm, Merlin C Thomas
Journal of Translational Internal Medicine|December 13, 2021
Advances in Clinical Research in Chronic Kidney DiseaseYutong Zou, Fang Liu, Mark E Cooper, et al.
Expert Opinion on Therapeutic Targets|October 11, 2022
Renal fibrosis as a hallmark of diabetic kidney disease: potential role of targeting transforming growth factor-beta (TGF-β) and related moleculesJiali Tang, Fang Liu, Mark E Cooper, et al.
Expert Opinion on Therapeutic Targets|June 4, 2019
Diabetic nephropathy: an insight into molecular mechanisms and emerging therapiesAnnabelle M Warren, Søren T Knudsen, Mark E Cooper
Expert Opinion on Pharmacotherapy|April 28, 2015
Recent advances in glucose-lowering treatment to reduce diabetic kidney diseaseNordin M J Hanssen, Nicholas Russell, Mark E Cooper
Journal of the American Society of Nephrology : JASN|November 26, 2003
Increased renal vascular endothelial growth factor and angiopoietins by angiotensin II infusion is mediated by both AT1 and AT2 receptorsBishoy Rizkalla, Josephine M Forbes, Mark E Cooper, et al.
Kidney International|May 24, 2013
Report on ISN Forefronts, Melbourne, Australia, 4-7 October 2012: tubulointerstitial disease in diabetic nephropathyJosephine M Forbes, David C H Harris, Mark E Cooper
Pageof 40

Showing results (81-90 of 399) with videos related to

Sort By:
Pageof 40
Lancet (London, England)|December 10, 2013
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and futureSteven E Kahn, Mark E Cooper, Stefano Del Prato
Current Atherosclerosis Reports|April 8, 2004
Use of genetic mouse models in the study of diabetic nephropathyTerri J Allen, Mark E Cooper, Hui Y Lan
Annals of the New York Academy of Sciences|May 2, 2008
Therapeutic interruption of advanced glycation in diabetic nephropathy: do all roads lead to Rome?Karly C Sourris, Josephine M Forbes, Mark E Cooper
Kidney International|September 17, 2005
Targets to retard the progression of diabetic nephropathyMark E Cooper, Karin Jandeleit-Dahm, Merlin C Thomas
Journal of Translational Internal Medicine|December 13, 2021
Advances in Clinical Research in Chronic Kidney DiseaseYutong Zou, Fang Liu, Mark E Cooper, et al.
Expert Opinion on Therapeutic Targets|October 11, 2022
Renal fibrosis as a hallmark of diabetic kidney disease: potential role of targeting transforming growth factor-beta (TGF-β) and related moleculesJiali Tang, Fang Liu, Mark E Cooper, et al.
Expert Opinion on Therapeutic Targets|June 4, 2019
Diabetic nephropathy: an insight into molecular mechanisms and emerging therapiesAnnabelle M Warren, Søren T Knudsen, Mark E Cooper
Expert Opinion on Pharmacotherapy|April 28, 2015
Recent advances in glucose-lowering treatment to reduce diabetic kidney diseaseNordin M J Hanssen, Nicholas Russell, Mark E Cooper
Journal of the American Society of Nephrology : JASN|November 26, 2003
Increased renal vascular endothelial growth factor and angiopoietins by angiotensin II infusion is mediated by both AT1 and AT2 receptorsBishoy Rizkalla, Josephine M Forbes, Mark E Cooper, et al.
Kidney International|May 24, 2013
Report on ISN Forefronts, Melbourne, Australia, 4-7 October 2012: tubulointerstitial disease in diabetic nephropathyJosephine M Forbes, David C H Harris, Mark E Cooper
Pageof 40